Relmada Therapeutics Inc
(NAS:RLMD)
$
0.3614
-0.0182 (-4.79%)
Market Cap: 10.90 Mil
Enterprise Value: -43.21 Mil
PE Ratio: 0
PB Ratio: 0.23
GF Score: 33/100 Relmada Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023 / 10:20PM GMT
Release Date Price:
$2.57
(-5.17%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst
Thanks, everyone, for joining us. Andrea Tan, biotech analyst at Goldman Sachs. With me, I have the team from Relmada, Sergio Traversa, CEO; and Cedric Gorman, CMO. Thank you so much for joining us.
Sergio Traversa
Relmada Therapeutics, Inc. - CEO & Director
Well, thank you for inviting us in this beautiful environment, and thanks for everyone that is listening to our webcast.
Questions & Answers
Andrea R. Tan;Sergio Traversa
Goldman Sachs Group, Inc., Research Division - Research Analyst;
Sergio, maybe I'll start with you. A lot has happened over the course of the last year, where we are now versus where we were last year when we were having this conversation. Maybe to level set here, maybe just provide an overview of what did happen across 2 of your clinical trials where you've had data readouts. And maybe what are the learnings that you took from that with respect to trial execution?
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot